The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of Biologics
- 22 December 2022
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 26 (3), 378-383
- https://doi.org/10.1016/j.jval.2022.12.010
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- May your drug price be evergreenJournal of Law and the Biosciences, 2018
- Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part DJAMA, 2018
- Strengths, weaknesses and future challenges of biosimilars’ development. An opinion on how to improve the knowledge and use of biosimilars in clinical practicePharmacological Research, 2017
- Determinants of Market Exclusivity for Prescription Drugs in the United StatesJAMA Internal Medicine, 2017
- Cancer Drugs: An International Comparison of Postlicensing Price InflationJournal of Oncology Practice, 2017
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016
- Cost–effectiveness thresholds in the USA: are they coming? Are they already here?Journal of Comparative Effectiveness Research, 2016
- The Value of Atorvastatin Over the Product Life Cycle in the United StatesClinical Therapeutics, 2011
- Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part IValue in Health, 2010
- Future Drug Prices and Cost-Effectiveness AnalysesPharmacoEconomics, 2008